Adenocarcinoma of the Prostate, Prostate Cancer
Conditions
Keywords
Prostate cancer, PSA level, docetaxel, estramustine, hormone therapy, androgen withdrawal
Brief summary
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug
Detailed description
* Patients will receive two medications; docetaxel and estramustine. Estramustine will be taken orally three times daily for 5 days starting on day one. Docetaxel will be given intravenously on day 2. These two drugs will be repeated every 3 weeks for a total of 4 cycles (12 weeks). * Patients will also take dexamethasone for three days at the beginning of each cycle to help decrease the risk of side effects. * Patients will also take coumadin every day for three months while on the chemotherapy to reduce the risk of blood clots. * After 12 weeks the chemotherapy phase will be completed and patient will start on the hormone therapy part of the treatment. Three weeks after the last chemotherapy treatment, patients will start Casodex orally once daily. * After taking Casodex for 1 week, patients will then start on Zoladex (an injection in the abdomen) every 3 months for a total of 5 injections. * During study treatment various blood tests will be performed to watch the disease. Study treatment will stop after a total of 18 months (3 months chemotherapy and 15 months hormone therapy). A physical exam and blood tests will be performed every 3 months for 2 years, every 4 months for the third year, and then every 6 months after that.
Interventions
DRUGDocetaxel
Given intravenously on day 2 of four three-week cycles
DRUGEstramustine
Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
DRUGCasodex
Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
DRUGZoladex
Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically documented adenocarcinoma of the prostate * Previous treatment with either radical prostatectomy or radiation therapy * Post prostatectomy: PSA rising on at least two successive occasions at least two weeks apart * Post radiation therapy alone: PSA has to be rising as documented on two successive occasions at least two weeks apart and also have doubled from the nadir post treatment value * ECOG performance status 0-1 * ANC \> 1,500/mm3 * Platelet counts \> 100,000/mm3 * SGOT and/or SGPT may be up to 2.5 x ULN
Exclusion criteria
* Documented local recurrence of prostate cancer or documented metastatic disease * History of other malignancy within the last 5 years, other than curatively treated basal cell carcinoma of the skin * Medical condition requiring the use of concommitant corticosteroids * Active infection * Significant cardiac disease, angina pectoris or myocardial infarction within six months * Prior chemotherapy including estramustine, suramin * Active thrombophlebitis or history of thromboembolic events in the six months preceding study treatment * Clinically significant neuropathy * Elevated bilirubin above ULN
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the feasibility of administering chemotherapy and medical castration to men with rising PSA after radical prostatectomy or radiation therapy. | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| To determine the PSA response rate and duration of response | — |
| to measure testosterone, free testosterone, and sex hormone binding globulin in relation to chemotherapy and hormone therapy. | 2 years |
Countries
United States
Outcome results
None listed